01-03-2024 | Daclatasvir | Retraction Note
Retraction Note: High success rates for the use of sofosbuvir/ombitasvir/paritaprevir/ritonavir + ribavirin and sofosbuvir/simeprevir/daclatasvir + ribavirin in retreatment of chronic hepatitis C infection after unsuccessful sofosbuvir/daclatasvir therapy: a real-life experience
Published in: Archives of Virology | Issue 3/2024
Login to get access